<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3112246508
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Xelorni 8 mg F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LORNOXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 389]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Arabian Japanese Pharmaceutical Co. Ltd.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="direction:ltr">Xelorni&reg; is a non-steroidal anti-inflammatory drug (NSAID) and antirheumatic drug of the oxicam class. It is intended for short term treatment of acute mild to moderate pain and symptoms of rheumatoid arthritis and osteoarthritis such as pain and inflammation of joints.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="direction:ltr">Do not take Xelorni&reg;</p><p style="direction:ltr">&bull; If you are allergic (hypersensitive) to lornoxicam or any of the other ingredients of Xelorni&reg;;</p><p style="direction:ltr">&bull; If you are taking other NSAIDs such as acetylsalicylic acid (for instance, aspirin); ibuprofen and COX-2 inhibitors;</p><p style="direction:ltr">&bull; If you are hypersensitive to other NSAIDs including acetylsalicylic acid (for instance, aspirin);</p><p style="direction:ltr">&bull; If you suffer from thrombocytopenia (low blood platelet count which increases risk of bleeding or bruising);</p><p style="direction:ltr">&bull; If you suffer from severe heart failure;</p><p style="direction:ltr">&bull; If you suffer from gastrointestinal bleeding, rupture and bleeding of a blood vessel in the brain, or other bleeding disorders;</p><p style="direction:ltr">&bull; If you have a history of gastrointestinal bleeding or perforation, related to previous therapy with NSAIDs;</p><p style="direction:ltr">&bull; If you suffer from an active peptic ulcer or have a history of recurrent peptic ulcer;</p><p style="direction:ltr">&bull; If you suffer from severe liver impairment;</p><p style="direction:ltr">&bull; If you suffer from severe kidney impairment;</p><p style="direction:ltr">&bull; If you are in the last three months of your pregnancy.</p><p style="direction:ltr">Take special care with Xelorni&reg;</p><p style="direction:ltr">&bull; If you have impaired kidney function;</p><p style="direction:ltr">&bull; If you have a history of high blood pressure and/or heart failure;</p><p style="direction:ltr">&bull; If you suffer from ulcerative colitis or crohn&rsquo;s disease;</p><p style="direction:ltr">&bull; If you have a history of bleeding tendency;</p><p style="direction:ltr">&bull; If you have a history of asthma;</p><p style="direction:ltr">&bull; If you suffer from SLE (lupus erythematosus, a rare immunological disease).</p><p style="direction:ltr">Your doctor may have to monitor you by laboratory tests on a frequent basis if</p><p style="direction:ltr">&bull; You suffer from blood coagulation disorder,</p><p style="direction:ltr">&bull; You suffer from impaired liver function,</p><p style="direction:ltr">&bull; You are elderly,</p><p style="direction:ltr">&bull; Or you will be treated with Xelorni&reg; for more than 3 months.</p><p style="direction:ltr">You should inform your doctor if you are going to be treated with heparin or tacrolimus, while taking at the same time Xelorni&reg;.</p><p style="direction:ltr">If you experience any unusual abdominal symptoms such as abdominal bleeding, skin reactions such as skin rash, damage to the internal lining of the nostrils, mouth, eyelids, ears, genitals or anus, or other signs of hypersensitivity, you should stop taking Xelorni&reg; and contact your doctor immediately.</p><p style="direction:ltr">Medicines such as Xelorni&reg; may be associated with a small increase of the risk of heart attack (myocardial infarction) or stroke. Any risk is more likely with high doses and prolonged treatment. Do not exceed the recommended dose or the duration of treatment.</p><p style="direction:ltr">You should discuss your treatment with your doctor or pharmacist if</p><p style="direction:ltr">&bull; You have heart problems,</p><p style="direction:ltr">&bull; You had previously a stroke,</p><p style="direction:ltr">&bull; Or you think that you might be at risk of developing these conditions (for example, if you have high blood pressure, diabetes or high cholesterol, or you are a smoker).</p><p style="direction:ltr">Avoid using Xelorni&reg; during varicella (chickenpox) infections.</p><p style="direction:ltr">Taking other medicines</p><p style="direction:ltr">Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p style="direction:ltr">Do not take Xelorni&reg; if you are taking other NSAIDs such as acetylsalicylic acid (for instance, aspirin), ibuprofen and COX-2 inhibitors. Ask your doctor or pharmacist if you are uncertain.</p><p style="direction:ltr">Xelorni&reg; may interfere with other medicines. Be particularly careful if you are taking any of the following:</p><p style="direction:ltr">&bull; Cimetidine - used in the treatment of heartburn and peptic ulcers;</p><p style="direction:ltr">&bull; Anticoagulants, such as heparin or phenprocoumon - used to prevent the formation of blood clots;</p><p style="direction:ltr">&bull; Corticosteroids;</p><p style="direction:ltr">&bull; Methotrexate - used in treatment of cancer and immunological diseases;</p><p style="direction:ltr">&bull; Lithium;</p><p style="direction:ltr">&bull; Immunosuppresive agents, such as ciclosporine or tacrolimus;</p><p style="direction:ltr">&bull; Heart medicines, such as digoxin, ACE inhibitors, beta-adrenergic blockers;</p><p style="direction:ltr">&bull; Diuretics;</p><p style="direction:ltr">&bull; Quinolone antibiotics;</p><p style="direction:ltr">&bull; Anti-platelet agents - medicines used to prevent heart attacks and strokes;</p><p style="direction:ltr">&bull; SSRI (Selective Serotonin Reuptake Inhibitors) &ndash; used in the treatment of depression;</p><p style="direction:ltr">&bull; Sulphonylureas, for instance glibenclamide - used in the management of diabetes;</p><p style="direction:ltr">&bull; Inducers and inhibitors of CYP2C9-isoenzymes (such as the antibiotic rifampicin or the antifungal medicine fluconazole), as they might have an effect on the way in which your body breaks down Xelorni&reg;;</p><p style="direction:ltr">&bull; Angiotensin II receptor blocker - used to treat high blood pressure, kidney damage due to diabetes and congestive heart failure;</p><p style="direction:ltr">&bull; Pemetrexed - used to treat some forms of lung cancer.</p><p style="direction:ltr">Taking Xelorni&reg; with food and drink</p><p style="direction:ltr">Xelorni&reg; film-coated tablets are intended for oral use. Take this medicine before meals with a sufficient amount of liquid.</p><p style="direction:ltr">Taking this medicine with food is not recommended because this may reduce its effectiveness.</p><p style="direction:ltr">Pregnancy and breast-feeding</p><p style="direction:ltr">Ask your doctor or pharmacist for advice before taking any medicine.</p><p style="direction:ltr">Fertility</p><p style="direction:ltr">Using Xelorni&reg; may impair fertility and is not recommended for women attempting to become pregnant. Women who have difficulties becoming pregnant, or who are undergoing investigation of infertility, should consult with a doctor and consider stopping treatment with Xelorni&reg;.</p><p style="direction:ltr">Pregnancy</p><p style="direction:ltr">During the first 6 months of pregnancy treatment with Xelorni&reg; is not recommended, unless explicitly advised by your doctor.</p><p style="direction:ltr">You must not take Xelorni&reg; during the last three months of your pregnancy.</p><p style="direction:ltr">Breastfeeding</p><p style="direction:ltr">If you are breastfeeding treatment with Xelorni&reg; is not recommended, unless explicitly advised by your doctor.</p><p style="direction:ltr">Driving and using machines</p><p style="direction:ltr">Xelorni&reg; has negligible or no influence on the ability to drive or use machinery.</p><p style="direction:ltr">Important information about some of the ingredients of Xelorni&reg;</p><p style="direction:ltr">Xelorni&reg; tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking the medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="direction:ltr">Always take Xelorni&reg; exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p style="direction:ltr">The usual dose for adults is 8 to 16 mg, divided in two or three doses per day. Do not take more than 16 mg a day.</p><p style="direction:ltr">The dose for patients with arthritis is 12 mg, divided in two or three doses per day. Do not take more than 16 mg a day.</p><p style="direction:ltr">If you have a liver or kidney impairment, do not take more than 12 mg (taken twice or three times a day) of this medicine.</p><p style="direction:ltr">Xelorni&reg; tablets must be swallowed with sufficient amounts of liquid. Do not take Xelorni&reg; with a meal, as food can reduce the effectiveness of Xelorni&reg;.</p><p style="direction:ltr">Xelorni&reg; is not recommended for children and adolescents below 18 years old, due to lack of data.</p><p style="direction:ltr">If you take more Xelorni&reg; than you should</p><p style="direction:ltr">Please contact your doctor or the pharmacist if you have taken more Xelorni&reg; than prescribed.</p><p style="direction:ltr">In case of an overdose, you may expect the following symptoms: nausea, vomiting, symptoms associated with central nervous system (such as dizziness or disturbances in vision).</p><p style="direction:ltr">If you forget to take Xelorni&reg;</p><p style="direction:ltr">Do not take a double dose to make up for a forgotten tablet.</p><p style="direction:ltr">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="direction:ltr">Like all medicines, Xelorni&reg; can cause side effects, although not everybody gets them.</p><p style="direction:ltr">Medicines such as Xelorni&reg; may be associated with a small increase in the risk of heart attack or stroke.</p><p style="direction:ltr">If you experience any unusual abdominal symptoms such as abdominal bleeding, skin reactions such as skin rash, damage to the internal lining of the nostrils, mouth, eyelids, ears, genitals or anus, or other signs of hypersensitivity, you should stop taking Xelorni&reg; and contact your doctor immediately.</p><p style="direction:ltr">If you get any of the following side effects, stop taking this medicine and tell your doctor immediately, or contact the emergency department at your nearest hospital:</p><p style="direction:ltr">&bull; Shortness of breath, chest pains, or ankle swelling appear or get worse;</p><p style="direction:ltr">&bull; Severe or continuous stomach pain or your stools become black;</p><p style="direction:ltr">&bull; Yellowing of the skin and eyes (jaundice) &ndash; these are signs of liver problems;</p><p style="direction:ltr">&bull; An allergic reaction - which can include skin problems such as ulcers or blistering, or swelling of the face, lips, tongue, or throat which may cause difficulty in breathing;</p><p style="direction:ltr">&bull; Fever, blistering eruption or inflammation especially on hands and feet or in the mouth area (stevens-johnson syndrome);</p><p style="direction:ltr">&bull; Exceptionally, serious infections of the skin in case of varicella (chickenpox).</p><p style="direction:ltr">Undesirable effects associated with using Xelorni&reg; are given below.</p><p style="direction:ltr">Common side effects (affect 1 to 10 users in 100)</p><p style="direction:ltr">&bull; Mild and passing headache and dizziness,</p><p style="direction:ltr">&bull; Nausea, abdominal pain, upset stomach, diarrhoea and vomiting.</p><p style="direction:ltr">Uncommon side effects (affect 1 to 10 users in 1,000)</p><p style="direction:ltr">&bull; Weight loss (anorexia), inability to sleep, depression;</p><p style="direction:ltr">&bull; Eye discharges (conjunctivitis);</p><p style="direction:ltr">&bull; Feeling dizzy, ringing in the ears (tinnitus);</p><p style="direction:ltr">&bull; Cardiac failure, irregular heartbeat, rapid heart rate, feeling blushed;</p><p style="direction:ltr">&bull; Constipation, excessive wind (flatulence), belching, dry mouth, gastritis, peptic ulcer, upper abdominal pain, duodenal ulcer, mouth ulcers;</p><p style="direction:ltr">&bull; Increase in liver function tests (as seen from blood tests) and feeling unwell (malaise);</p><p style="direction:ltr">rash, itching, increased sweating, redness of the skin (erythema), angiooedema (rapid swelling of the deeper layers of skin, usually of the face), hives (urticaria), oedema, stuffy nose as a result of an allergy (rhinitis);</p><p style="direction:ltr">&bull; Hair loss;</p><p style="direction:ltr">&bull; Arthralgia (pain in the joints).</p><p style="direction:ltr">Rare side effects (affects 1 to 10 users in 10,000)</p><p style="direction:ltr">&bull; Sore throat;</p><p style="direction:ltr">&bull; Anaemia, reduction in the blood cell count (thrombocytopenia and leukopenia), weakness;</p><p style="direction:ltr">&bull; Hypersensitivity, anaphylactoid reaction and anaphylaxis (organism reaction characterized usually by face swelling, flushing, difficulties breathing and lightheadedness);</p><p style="direction:ltr">&bull; Confusion, nervousness, agitation, feeling sleepy (somnolence), paraesthesia (tingling sensations), abnormal sense of taste, tremor, migraine, visual disturbances;</p><p style="direction:ltr">&bull; Elevated blood pressure, hot flush;</p><p style="direction:ltr">&bull; Bleeding, haematoma (bruising), prolonged bleeding time;</p><p style="direction:ltr">&bull; Difficulty in breathing (dyspnoea), cough, bronchospasm;</p><p style="direction:ltr">&bull; Perforated ulcer, vomiting of blood, gastrointestinal bleeding, black tarry stools;</p><p style="direction:ltr">&bull; Inflammation in the mouth, oesophagitis (inflammation of the gullet), gastro oesophageal reflux, difficulty in swallowing, aphthous stomatitis (ulcers), inflammation of the tongue,</p><p style="direction:ltr">&bull; Abnormal liver function;</p><p style="direction:ltr">&bull; Skin problems, such as eczema, rash;</p><p style="direction:ltr">&bull; Bone pain, muscle cramp, muscle pain;</p><p style="direction:ltr">&bull; Urinary problems, such as the need to wake up and urinate during the night (nocturnia) or an increase in the levels of urea and creatinine in the blood.</p><p style="direction:ltr">Very rare side effects (affect less than 1 user in 10,000)</p><p style="direction:ltr">&bull; Liver damage, hepatitis (inflammation of the liver), jaundice, cholestasis (interrupted flow of bile from the liver);</p><p style="direction:ltr">&bull; Bruising, oedema, severe skin disorder (Stevens-Johnson syndrome, Toxic epidermal necrolysis);</p><p style="direction:ltr">&bull; Aseptic meningitis;</p><p style="direction:ltr">&bull; NSAID class effects: neutropenia, agranulocytosis, aplastic anaemia, hemolytic anaemia, kidney toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="direction:ltr">Store below 30&deg;C.</p><p style="direction:ltr">Keep out of the reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="direction:ltr">Active ingredient: Lornoxicam, each tablet contains 8 mg lornoxicam (as hydrochloride)</p><p style="direction:ltr">Other ingredients:</p><p style="direction:ltr">Lactose</p><p style="direction:ltr">PVP</p><p style="direction:ltr">Croscarmellose sodium&nbsp;&nbsp;</p><p style="direction:ltr">Avicel</p><p style="direction:ltr">Magnesium Stearate</p><p style="direction:ltr">Opadry white</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White to creamy oval shaped film coated tablet imposed with SJ33C in one side. 
Pack contains 3 blisters (each blister have 10 tablets total tablets in unit carton 30 tablets).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited</p><p>Jeddah - Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Apr/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي زيلورني إلى مجموعة من الأدوية تسمى &quot;مضادات الالتهاب غير الستيرويدية&quot; (NSAIDs) من فئة أوكسيكام.</p><p dir="RTL">ويستخدم في العلاج قصير المدى للألم الحاد الطفيف إلى المتوسط وأعراض الالتهاب الروماتويدي والتهاب المفاصل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تأخذ زيلورني</p><p dir="RTL">&bull; إذا كان لديك حساسية (فرط الحساسية) من لورنوكسيكام أو أي من المكونات الأخرى من زيلورني.</p><p dir="RTL">&bull; إذا كنت تتناول مضادات الالتهاب غير الستيروئيدية الأخرى مثل حمض الأسيتيل ساليسيليك (على سبيل المثال، الأسبرين)؛ إيبوبروفين و مثبطات كوكس-2.</p><p dir="RTL">&bull; إذا كنت تعاني من فرط الحساسية لمضادات الالتهاب غير الستيرويدية الأخرى بما في ذلك حمض الأسيتيل ساليسيليك (على سبيل المثال، الأسبرين).</p><p dir="RTL">&bull; إذا كنت تعاني من نقص الصفيحات( انخفاض عدد الصفائح الدموية مما يزيد من خطر النزيف أو الكدمات ).</p><p dir="RTL">&bull; إذا كنت تعاني من قصور حاد في القلب.</p><p dir="RTL">&bull; إذا كنت تعاني من نزيف في الجهاز الهضمي، وتمزق ونزيف لأوعية دموية في الدماغ، أو اضطرابات نزيف أخرى.</p><p dir="RTL">&bull; إذا كان لديك تاريخ من نزيف الجهاز الهضمي أو انثقاب، تتعلق العلاج السابق مع مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">&bull; إذا كنت تعاني من قرحة هضمية نشطة أو لديك تاريخ من القرحة الهضمية المتكررة.</p><p dir="RTL">&bull; إذا كنت تعاني من ضعف كبدي حاد.</p><p dir="RTL">&bull; إذا كنت تعاني من قصور شديد في الكلى.</p><p dir="RTL">&bull; إذا كنت في الأشهر الثلاثة الأخيرة من الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توخ الحذر مع زيلورني</p><p dir="RTL">&bull; إذا كان لديك ضعف في وظائف الكلى.</p><p dir="RTL">&bull; إذا كان لديك تاريخ من ارتفاع ضغط الدم و / أو قصور القلب.</p><p dir="RTL">&bull; إذا كنت تعاني من التهاب القولون التقرحي أو مرض كرون.</p><p dir="RTL">&bull; إذا كان لديك تاريخ من نزيف.</p><p dir="RTL">&bull; إذا كان لديك تاريخ من الربو.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض الذئبة الحمراء (الذئبة الحمامية، مرض مناعي نادر).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يحتاج طبيبك لمتابعة حالتك عن طريق الاختبارات المعملية على أساس متكرر إذا</p><p dir="RTL">&bull; كنت تعاني من اضطراب تخثر الدم،</p><p dir="RTL">&bull; كنت تعاني من ضعف وظائف الكبد،</p><p dir="RTL">&bull; كنت من كبار السن،</p><p dir="RTL">&bull; أو سيتم استخدام زيلورني لأكثر من 3 أشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك إبلاغ الطبيب إذا كنت ستعالج بالهيبارين أو تاكروليموس، أثناء تناولك زيلورني في نفس الوقت.</p><p dir="RTL">إذا واجهت أي أعراض غير طبيعية في البطن مثل نزيف البطن، الطفح الجلدي، وتلف البطانة الداخلية من فتحتي الأنف والفم والجفون والأذنين والأعضاء التناسلية أو فتحة الشرج، أو غيرها من علامات فرط الحساسية، يجب التوقف عن تناول زيلورني واتصل بطبيبك فورا.</p><p dir="RTL">قد تترافق الأدوية مثل زيلورني مع زيادة صغيرة في خطر الإصابة بأزمة قلبية (احتشاء عضلة القلب) أو السكتة الدماغية. أي خطر أكثر احتمالا مع جرعات عالية والعلاج لفترات طويلة. لا تتجاوز الجرعة الموصى بها أو مدة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك مناقشة علاجك مع طبيبك أو الصيدلي إذا</p><p dir="RTL">&bull; لديك مشاكل في القلب،</p><p dir="RTL">&bull; كان لديك سابقا السكتة الدماغية،</p><p dir="RTL">&bull; أو تعتقد أنك قد تكون معرضا لخطر تطور هذه الظروف على سبيل المثال، إذا كان لديك ارتفاع ضغط الدم أو السكري أو ارتفاع الكولسترول أو كنت مدخنا.</p><p dir="RTL">تجنب استخدام زيلورني أثناء الإصابة بالحماق (جدري الماء).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول أدوية أخرى</p><p dir="RTL">یرجی إخبار الطبیب أو الصیدلي إذا کنت تتناول أو تناولت مؤخرا أدویة أخرى، بما في ذلك الأدویة التي تم الحصول علیھا بدون وصفة طبیة.</p><p dir="RTL">لا تأخذ زيلورني إذا كنت تأخذ مضادات الالتهاب غير الستيرويدية الأخرى مثل الأسيتيل ساليسيليك (على سبيل المثال، الأسبرين)، إيبوبروفين و مثبطات كوكس-2. اسأل طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">زيلورني قد يتداخل مع أدوية أخرى. كن حذرا بشكل خاص إذا كنت تناول أي مما يلي:</p><p dir="RTL">&bull; سيميتيدين - يستخدم في علاج حرقة المعدة والقرحة الهضمية.</p><p dir="RTL">&bull; مضادات التخثر، مثل الهيبارين أو الفينبروكومون - تستخدم لمنع تشكيل جلطات الدم.</p><p dir="RTL">&bull; الكورتيزون.</p><p dir="RTL">&bull; الميثوتريكسيت - المستخدم في علاج السرطان والأمراض المناعية.</p><p dir="RTL">&bull; ليثيوم.</p><p dir="RTL">&bull; مثبط مناعة، مثل السيكلوسبورين أو تاكروليموس.</p><p dir="RTL">&bull; أدوية القلب، مثل الديجوكسين، مثبطات إيس، حاصرات بيتا الأدرينالية.</p><p dir="RTL">&bull; مدرات البول.</p><p dir="RTL">&bull; المضادات الحيوية كينولون.</p><p dir="RTL">&bull; الأدوية المضادة للصفائح الدموية - الأدوية المستخدمة لمنع النوبات القلبية والسكتات الدماغية.</p><p dir="RTL">&bull; مثبطات امتصاص السيروتونين الانتقائية - المستخدمة في علاج الاكتئاب.</p><p dir="RTL">&bull; مجموعة أدوية سولفونيل يوريا، على سبيل المثال غليبين كلاميد - المستخدمة في علاج مرض السكري.</p><p dir="RTL">&bull; المحفزات ومثبطات الإنزيمات CYP2C9 (مثل المضاد الحيوي ريفامبيسين أو فلوكونازول الدواء المضاد للفطريات)، لأنها قد يكون لها تأثير على الطريقة التي يتخلص بها جسمك من زيلورني.</p><p dir="RTL">&bull; مانع مستقبلات أنجيوتنسين الثاني - يستخدم لعلاج ارتفاع ضغط الدم، تلف الكلى بسبب مرض السكري وفشل القلب الاحتقاني.</p><p dir="RTL">&bull; بيميتريكسد - يستخدم لعلاج بعض أشكال سرطان الرئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول زيلورني مع الطعام والشراب</p><p dir="RTL">زيلورني أقراص مغلفة للاستخدام عن طريق الفم. تناول هذا الدواء قبل وجبات الطعام مع كمية كافية من السائل.</p><p dir="RTL">لا ينصح باستخدام هذا الدواء مع الطعام لأن ذلك قد يقلل من فاعليته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل والرضاعة الطبيعي</p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الخصوبة</p><p dir="RTL">استخدام زيلورني قد يضعف الخصوبة ولا يُوصى به للمرأة التى تريد الانجاب. يجب على النساء اللواتي يعانين من صعوبات في الحمل، استشارة الطبيب والنظر في وقف العلاج بزيلورني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل</p><p dir="RTL">لا ينصح به خلال الأشهر الستة الأولى من الحمل، ما لم ينصح الطبيب.</p><p dir="RTL">يجب ألا تتناولي زيلورني خلال الأشهر الثلاثة الأخيرة من الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الرضاعة الطبيعية</p><p dir="RTL">لا ينصح به مع الرضاعة الطبیعیة، إلا إذا نصحك الطبیب صراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL">زيلورني له تأثير ضئيل أو لا يؤثر على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">معلومات هامة عن بعض المكونات من زيلورني</p><p dir="RTL">زيلورني أقراص يحتوي على مونوهيدرات اللاكتوز. إذا قيل لك من قبل طبيبك أن لديك حساسية لبعض السكريات، اتصل بطبيبك قبل تناول المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائما على تناول زيلورني تماما كما أخبرك طبيبك. يجب عليك مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">الجرعة المعتادة للبالغين هي 8 إلى 16 ملج، مقسمة إلى جرعتين أو ثلاث جرعات في اليوم. لا تأخذ أكثر من 16 ملج يوميا.</p><p dir="RTL">الجرعة للمرضى الذين يعانون من التهاب المفاصل هو 12 ملج، مقسمة إلى جرعتين أو ثلاث جرعات في اليوم الواحد. لا تأخذ أكثر من 16 ملج يوميا.</p><p dir="RTL">إذا كنت تعاني من ضعف في الكبد أو الكلى، لا تأخذ أكثر من 12 ملج تؤخذ على مرتين أو ثالث مرات يوميا.</p><p dir="RTL">يجب ابتلاع أقراص زيلورني مصحوبةً بكميات كافية من السائل. لا تأخذ زيلورني مع وجبة، حيث أن الغذاء يمكن أن يقلل من فاعلية زيلورني.</p><p dir="RTL">لا يُنصح زيلورني للأطفال والمراهقين الذين تقل أعمارهم عن 18 سنة، وذلك بسبب نقص البيانات.</p><p dir="RTL">إذا تناولت كمية من زيلورني أكثر مما يجب</p><p dir="RTL">يرجى الاتصال بطبيبك أو الصيدلي إذا كنت قد أخذت جرعة من زيلورني أكثر من المنصوص عليها.</p><p dir="RTL">في حالة الجرعة الزائدة، قد تتوقع الأعراض التالية: الغثيان، والتقيؤ، والأعراض المرتبطة بالجهاز العصبي المركزي (مثل الدوخة أو اضطرابات في الرؤية).</p><p dir="RTL">إذا نسيت أن تأخذ زيلورني</p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، زيلورني يمكن أن يسبب آثار جانبية، وإن لم تكن تحصل للجميع.</p><p dir="RTL">قد تترافق الأدوية مثل زيلورني مع زيادة صغيرة في خطر الإصابة بأزمة قلبية أو السكتة الدماغية.</p><p dir="RTL">إذا واجهت أي أعراض غير طبيعية في البطن مثل نزيف البطن، الطفح الجلدي، وتلف البطانة الداخلية من فتحتي الأنف والفم والجفون والأذنين والأعضاء التناسلية أو فتحة الشرج، أو غيرها من علامات فرط الحساسية، يجب التوقف عن تناول زيلورني واتصل بطبيبك فورا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث أي من الآثار الجانبية التالية، توقف عن تناول هذا الدواء وأخبر طبيبك فوراً، أو اتصل بقسم الطوارئ في أقرب مستشفى:</p><p dir="RTL">&bull; ضيق في التنفس، آلام في الصدر، أو تورم في الكاحل تظهر أو تزداد سوءا.</p><p dir="RTL">&bull; آلام في المعدة شديدة أو مستمرة أو يصبح البراز أسوداً.</p><p dir="RTL">&bull; اصفرار الجلد والعينين (اليرقان) - وهذه هي علامات مشاكل الكبد.</p><p dir="RTL">&bull; مشاكل في الجلد مثل القرحة أو تورم في الوجه أو الشفاه أو اللسان أو الحلق مما قد يسبب صعوبة في التنفس.</p><p dir="RTL">&bull; متلازمة ستيفنز جونسون.</p><p dir="RTL">&bull; عدوى الجلد الخطيرة كما في حالة الحماق (جدري الماء).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وترد أدناه الآثار غير المرغوب فيها المرتبطة باستخدام زيلورني.</p><p dir="RTL">الآثار الجانبية الشائعة (تؤثر على 1 إلى 10 مستخدمين في 100)</p><p dir="RTL">&bull; صداع معتدل ودوار.</p><p dir="RTL">&bull; الغثيان، ألم في البطن، اضطراب في المعدة، الإسهال والقيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية غير شائعة (تؤثر على 1 إلى 10 مستخدمين في 1.000)</p><p dir="RTL">&bull; فقدان الوزن (فقدان الشهية)، وعدم القدرة على النوم، والاكتئاب.</p><p dir="RTL">&bull; إفرازات العين (التهاب الملتحمة).</p><p dir="RTL">&bull; الشعور بالدوار، رنين في الأذنين (طنين).</p><p dir="RTL">&bull; الفشل القلبي، وعدم انتظام ضربات القلب، ومعدل ضربات القلب السريع والشعور باحمرار الوجه.</p><p dir="RTL">&bull; الإمساك، وخروج الريح المفرط (انتفاخ البطن)، والتجشؤ، وجفاف الفم، التهاب المعدة، وقرحة المعدة، وآلام في أعلى البطن، قرحة الاثني عشر، تقرحات الفم.</p><p dir="RTL">&bull; زيادة في اختبارات وظائف الكبد (كما يتضح من اختبارات الدم) والشعور بالتوعك.</p><p dir="RTL">&bull; طفح جلدي، حكة، زيادة في التعرق، احمرار في الجلد (حمامي)، وذمة وعائية (تورم سريع للطبقات العميقة من الجلد، عادة من الوجه)، الشرى، وذمة، انسداد الأنف نتيجة للحساسية (التهاب الأنف).</p><p dir="RTL">&bull;تساقط الشعر.</p><p dir="RTL">&bull; ألم مفصلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية نادرة (تؤثر على 1 إلى 10 مستخدمين في 10.000)</p><p dir="RTL">&bull;إلتهاب الحلق.</p><p dir="RTL">&bull; فقر الدم، وانخفاض في عدد خلايا الدم (نقص الصفيحات وقلة الكريات البيض)، وضعف.</p><p dir="RTL">&bull; فرط الحساسية، رد الفعل التحسسي والتفاعل المفرط (الحساسية تتميز عادة بتورم الوجه، واحمرار ، وصعوبة التنفس والدوار).</p><p dir="RTL">&bull; الارتباك، والعصبية، والإثارة، والشعور بالنعاس (نعاس)، والشعور غير طبيعي من الذوق، ورعاش، والصداع النصفي، واضطرابات بصرية.</p><p dir="RTL">&bull; ارتفاع ضغط الدم، هبات الحرارة.</p><p dir="RTL">&bull; النزيف، ورم دموي (كدمات)، و النزيف لفترات طويلة.</p><p dir="RTL">&bull; صعوبة في التنفس ، والسعال، تشنج قصبي.</p><p dir="RTL">&bull; قرحة مثقبة، قيء الدم، نزيف الجهاز الهضمي، براز أسود.</p><p dir="RTL">&bull; التهاب في الفم، التهاب المري (التهاب المريء)، وصعوبة في البلع، قرحة فموية (القرحة)، والتهاب اللسان.</p><p dir="RTL">&bull; اختلال وظائف الكبد.</p><p dir="RTL">&bull; مشاكل الجلد، مثل الأكزيما والطفح الجلدي.</p><p dir="RTL">&bull; آلام العظام، وتشنج العضلات، وآلام في العضلات.</p><p dir="RTL">&bull; مشاكل في البول، مثل الحاجة إلى الاستيقاظ والتبول أثناء الليل أو زيادة في مستويات اليوريا والكرياتينين في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية نادرة جدا (تؤثر على أقل من 1 المستخدم في 10.000)</p><p dir="RTL">&bull; تلف الكبد، التهاب الكبد، اليرقان، ركود صفراوي (توقف تدفق الصفراء من الكبد).</p><p dir="RTL">&bull; كدمات، وذمة، واضطراب الجلد الشديد (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي).</p><p dir="RTL">&bull; التهاب السحايا العقيم.</p><p dir="RTL">&bull; آثار فئة أدوية مضادات الالتهاب غير الستيرويدية: قلة العدلات، ندرة المحببات، فقر الدم اللاتنسجي، فقر الدم الانحلالي، تسمم الكلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي لورنوكسيكام. يحتوي كل قرص على 8 ملج لورنوكسيكام (على هيئة هيدروكلوريد).</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">لاكتوز</p><p dir="RTL">بي في بي</p><p dir="RTL">كروسكارميلوز الصوديوم</p><p dir="RTL">أفيسل</p><p dir="RTL">سترات الماغنيسيوم</p><p dir="RTL">أوبادراي أبيض</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص بيضاوية ذات لون أبيض مائل إلى بيج منقوش على أحد جانبيها&nbsp; SJ33C.</p><p dir="RTL">تحتوي العبوة على 30 قرصاً عبارة عن 3 شرائط في كل شريط 10 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مصنع ساجا للصناعات الدوائية&nbsp;&nbsp;</p><p dir="RTL">الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p dir="RTL">جدة &ndash; المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أبريل/ ٢٠١٨
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xelorni 8 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One film-coated tablet contains 8 mg lornoxicam
Excipients: Lactose 90 mg
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
White to creamy oval shaped film coated tablet imposed with SJ33C on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><div style="direction:ltr"><span style="text-align:unset">- Short-term relief of acute mild to moderate pain</span></div><div style="direction:ltr"><span style="text-align:unset">- Symptomatic relief of pain and inflammation in osteoarthritis.</span></div><table style="direction:ltr; width:1369px"><tbody><tr><td>-</td><td style="width:1365px">Symptomatic relief of pain and inflammation in rheumatoid arthritis</td></tr></tbody></table><p>&nbsp;</p><div style="direction:ltr">&nbsp;</div><div style="direction:ltr">&nbsp;</div>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table style="direction:ltr; width:1372px"><tbody><tr><td style="width:1372px">For all patients the appropriate dosing regimen should be based upon individual response</td></tr><tr><td style="width:1372px">to treatment.</td></tr><tr><td style="width:1372px">Pain</td></tr><tr><td style="width:1372px">8-16 mg lornoxicam daily divided into 2 or 3 doses. Maximum recommended daily dose</td></tr><tr><td style="width:1372px">is 16 mg.</td></tr><tr><td style="width:1372px">Osteoarthritis and Rheumatoid arthritis</td></tr><tr><td style="width:1372px">Initial recommended dose is 12 mg lornoxicam daily divided into 2 or 3 doses.</td></tr><tr><td style="width:1372px">Maintenance dose should not exceed 16 mg lornoxicam daily.</td></tr><tr><td style="width:1372px">Xelorni film-coated tablets are supplied for oral use and should be taken with a sufficient</td></tr><tr><td style="width:1372px">quantity of liquid.</td></tr></tbody></table><p>&nbsp;</p><div style="direction:ltr">&nbsp;</div><div style="direction:ltr">&nbsp;</div><div style="direction:ltr"><span style="text-align:unset">Additional information on special populations</span></div><div style="direction:ltr"><span style="text-align:unset">Children and adolescents</span></div><div style="direction:ltr"><span style="text-align:unset">Lornoxicam is not recommended for use in children and adolescents below age 18 due to</span></div><div style="direction:ltr"><span style="text-align:unset">a lack of data on safety and efficacy.</span></div><div style="direction:ltr"><span style="text-align:unset">Elderly</span></div><div style="direction:ltr"><span style="text-align:unset">No special dosage modification is required for elderly patients above age 65 unless renal</span></div><div style="direction:ltr"><span style="text-align:unset">or hepatic function is impaired. Lornoxicam should be administered with precaution as</span></div><div style="direction:ltr"><span style="text-align:unset">gastrointestinal adverse effects are less well tolerated in this group (see section 4.4).</span></div><div style="direction:ltr"><span style="text-align:unset">Renal impairment</span></div><div style="direction:ltr"><span style="text-align:unset">For patients with mild to moderate renal impairment the maximum recommended daily</span></div><div style="direction:ltr"><span style="text-align:unset">dose is 12 mg divided in 2 or 3 doses (see section 4.4).</span></div><div style="direction:ltr"><span style="text-align:unset">Hepatic impairment</span></div><div style="direction:ltr"><span style="text-align:unset">For patients with moderate hepatic impairment the maximum recommended daily dose is</span></div><div style="direction:ltr"><span style="text-align:unset">12 mg divided in 2 or 3 doses (see section 4.4).</span></div><div style="direction:ltr"><span style="text-align:unset">Undesirable effects may be minimised by using the lowest effective dose for the shortest</span></div><div style="direction:ltr"><span style="text-align:unset">duration necessary to control symptoms (see section 4.4.).</span></div>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to lornoxicam or any of the excipients
- Thrombocytopenia
- Hypersensitivity (symptoms like asthma, rhinitis, angioedema or urticaria) to
other NSAIDs including acetylsalicylic acid
- Severe heart failure
- Gastro-intestinal bleeding, cerebrovascular bleeding or other bleeding disorders
- History of gastrointestinal bleeding or perforation, related to previous NSAIDs
therapy
- Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct
episodes of proven ulceration or bleeding)
- Severe hepatic impairment
- Severe renal impairment (Serum creatinine > 700 µmol/l)
- The third trimester of pregnancy (see section 4.6)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">For the following disorders, lornoxicam should only be administered after careful risk- benefit assessment:</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment: Lornoxicam should be administered with precaution in patients with mild (serum creatinine 150-300 &micro;mol/l) to moderate (serum creatinine 300</p><p style="direction:ltr">&ndash; 700 &micro;mol/l) renal impairment due to dependency on renal prostaglandins for maintenance of renal blood flow. Treatment with lornoxicam should be discontinued if renal function deteriorates during treatment.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal functions should be monitored in patients who undergo major surgery, with cardiac failure, receiving treatment with diuretics, receiving concomitant treatment with drugs that are suspected to or known to be able to cause kidney damage.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with blood coagulation disorders: Careful clinical monitoring and laboratory assessment is recommended (e.g. APTT).</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic impairment (e.g. liver cirrhosis): Clinical monitoring and laboratory assessments at regular intervals should be considered in patients with hepatic impairment as accumulation of lornoxicam (increase in AUC) may occur after treatment with daily doses of 12-16 mg. Apart from that, hepatic impairment does not seem to affect pharmacokinetic parameters of lornoxicam as compared to healthy subjects.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long term treatment (longer than 3 months): Regular laboratory assessments of haematology (haemoglobin), renal functions (creatinine) and liver enzymes are recommended.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elderly patients above 65 years: Monitoring of renal and hepatic function is recommended.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Precaution is advised in elderly postoperative patients.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">The use of lornoxicam with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Undesirable effects may be minimised by using lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and GI and cardiovascular risks below).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Gastrointestinal bleeding, ulceration and perforation: GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose acetylsalicylic acid or other active substances likely to increase gastrointestinal risk (see below and section 4.5). Clinical monitoring at regular intervals is recommended.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Caution should be advised in patients receiving concomitant medicinal products which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">When GI bleeding or ulceration occurs in patients receiving lornoxicam, the treatment should be withdrawn.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">NSAIDs should be given with care to patients with a history of gastrointestinal disease</p><p style="direction:ltr">(ulcerative colitis, Crohn&rsquo;s disease) as their condition may be exacerbated (see section</p><p style="direction:ltr">4.8).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.3).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Caution is required in patients with a history of hypertension and/or heart failure as fluid retention and oedema have been reported in association with NSAID therapy.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for lornoxicam.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Lornoxicam after careful consideration. Similar consideration should be</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Concomitant treatment with NSAIDs and heparin in the context of a spinal or epidural anaesthesia increases the risk of spinal/epidural haematoma (see section 4.5).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens- Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Lornoxicam should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Lornoxicam reduces platelet aggregation and prolongs bleeding time and consequently care should be taken when administering to patients with increased bleeding tendency.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Concomitant treatment of NSAIDs and tacrolimus may increase the risk of nephrotoxicity owing to reduced synthesis of prostacyclin in the kidney. Renal function must therefore be monitored closely in patients receiving combination therapy.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">As with most NSAIDs occasional increase in serum transaminases level, increase in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen as well as other laboratory abnormalities have been reported. Should any such abnormality prove significant or persist the administration of lornoxicam should be stopped and appropriate investigations prescribed.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">The use of lornoxicam, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of lornoxicam should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr"><u>Concomitant administration of lornoxicam and</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cimetidine: Increased plasma concentrations of lornoxicam. (No interaction between lornoxicam and ranitidine, or lornoxicam and antacids has been demonstrated).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4). Careful monitoring of INR should be undertaken</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenprocoumon: Decreased effect of phenprocoumon treatment.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heparin: NSAIDs increase the risk of spinal or epidural haematoma when given concomitantly to heparin in the context of spinal or epidural anaesthesia.</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACE inhibitors: The antihypertensive effect of the ACE inhibitor may decrease.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diuretics: Decreased diuretic and antihypertensive effect of loop diuretics and thiazide diuretics.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-adrenergic blockers: Decreased antihypertensive efficacy.</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin: Decreased renal clearance of digoxin.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids: Increased risk of gastrointestinal ulceration or bleeding (see section 4.4).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinolone antibiotics: Increased risk of seizures.</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-platelet agents: Increased risk of gastrointestinal bleeding (see section 4.4).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other NSAIDs: Increased risk of gastrointestinal bleeding.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate: Increased serum concentration of methotrexate. Increased toxicity may result.</p><p style="direction:ltr">When concomitant therapy has to be used careful monitoring should be undertaken.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding (see section 4.4).</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium: NSAIDs inhibit renal clearance of lithium, thus the serum concentration of lithium may increase above toxicity limits. Therefore serum lithium levels require monitoring, especially during initiation, adjustment and withdrawal of treatment.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporine: Increased serum concentration of cyclosporine. Nephrotoxicity of cyclosporine may be enhanced via renal prostaglandin mediated effects. During combined treatment renal function should be monitored.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulphonylureas: Increased risk of hypoglycaemia.</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Known inducers and inhibitors of CYP2C9 isoenzymes: Lornoxicam (as other NSAIDs depending on the cytochrome P450 2C9 (CYP2C9 isoenzyme)) has interactions with known inducers and inhibitors of CYP2C9 isoenzymes (see section 5.2</p><p style="direction:ltr">Biotransformation).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tacrolimus: Increase the risk of nephrotoxicity owing to reduced synthesis of prostacyclin in the kidney. During combined treatment renal function should be monitored.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Food may decrease the absorption with about 20% and increase Tmax.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr"><strong>P</strong><strong>r</strong><strong>e</strong><strong>gnancy Category: C Pregnancy</strong></p><p style="direction:ltr">Lornoxicam is contraindicated on the third trimester of pregnancy and should not be used during pregnancy in the first and second trimesters and delivery as no clinical data on</p><p style="direction:ltr">exposed pregnancies are available.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">There are no adequate data from the use of lornoxicam in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post implantation loss and embryo- foetal lethality. During the first and second trimester of pregnancy, prostaglandin synthesis inhibitors should not be given unless clearly necessary.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Prostaglandin synthesis inhibitors administered during the third trimester of pregnancy may expose the foetus to cardiopulmonary toxicity (premature closure of the ductus arteriosus and pulmonary hypertension) and renal dysfunction which may lead to renal failure and hence a reduced quantity of amniotic fluid. At the end of pregnancy, prostaglandin synthesis inhibitors may expose the mother and the foetus to increased bleeding time and inhibition of uterine contractions, which may delay or prolong the labour. Therefore, the use of lornoxicam is contraindicated during the third trimester of pregnancy (see section 4.3).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><strong>Lactation</strong></p><p style="direction:ltr">There are no data on the excretion of lornoxicam in human breast milk. Lornoxicam is excreted in milk of lactating rats in relatively high concentrations. Therefore lornoxicam should not be used in breastfeeding women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">Patients showing dizziness and/or sleepiness under treatment with lornoxicam should refrain from driving or operation machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr"><u>A. Summary of Side effects</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&rsquo;s disease (see section 4.4) have been reported following administration of</p><p style="direction:ltr">NSAIDs. Less frequently, gastritis has been observed.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Approximately 20% of patients treated with lornoxicam can be expected to experience adverse reactions. The most frequent adverse effects of lornoxicam include nausea, dyspepsia, indigestion, abdominal pain, vomiting, and diarrhoea. These symptoms have generally occurred in less than 10% of patients in available studies.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Oedema, hypertension, and cardiac failure, have been reported in association with</p><p style="direction:ltr">NSAID treatment.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>B</u><u>. Tabulated list of adverse events</u></p><p style="direction:ltr">Listed below are undesirable effects which generally occurred in more than 0.05% of the</p><p style="direction:ltr">6.417 patients treated in clinical phase II, III and IV trials.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Very common (</u><u>&sup3; </u><u>1/10); Common (</u><u>&sup3; </u><u>1/100, &lt;1/10); Uncommon (</u><u>&sup3; </u><u>1/1000, &lt;1/100); rare</u></p><p style="direction:ltr"><u>(</u><u>&sup3; </u><u>1/10.000, &lt;1/1.000); Very rare (&lt;1/10.000).</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>I</u><u>n</u><u>fections and infestations</u></p><p style="direction:ltr">Rare: Pharyngitis.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>B</u><u>lood and the lymphatic system disorders</u></p><p style="direction:ltr">Rare: Anaemia, thrombocytopenia, leucopoenia, prolonged bleeding time</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Very rare: Ecchymosis.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>I</u><u>mmune system disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Rare: Hypersensitivity.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Metabolism and nutrition disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Anorexia, weight changes.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>P</u><u>s</u><u>y</u><u>c</u><u>hiatric disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Insomnia, depression.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Rare: Confusion, nervousness, agitation.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Nervous system disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Common: Mild and transient headache, dizziness.</p><p style="direction:ltr">Rare: Somnolence, paraesthesia, dysgeusia, tremor, migraine.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>E</u><u>y</u><u>e disorders</u></p><p style="direction:ltr">Uncommon: Conjuctivitis</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Rare: Visual disturbances.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Ear and labyrinth disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Vertigo, tinnitus.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Cardiac disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Palpitations, tachycardia, oedema, cardiac failure.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Vascular disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Flushing, oedema.</p><p style="direction:ltr">Rare: Hypertension, hot flush, haemorrhage, haematoma.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Respiratory, thoracic and mediastinal disorders</u></p><p style="direction:ltr">Uncommon: Rhinitis.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Rare: Dyspnoea, cough, bronchospasm.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Gastrointestinal disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Common: Nausea, abdominal pain, dyspepsia, diarrhoea, vomiting.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Constipation, flatulence, eructation, dry mouth, gastritis, gastric ulcer, abdominal pain upper, duodenal ulcer, mouth ulceration.</p><p style="direction:ltr">Rare: Melaena, haematemesis, stomatitis, oesophagitis, gastrooesophageal reflux, dysphagia, aphthous stomatitis, glossitis, perforated peptic ulcer.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Hepatobiliary disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Increase in liver function tests, SGPT (ALT) or SGOT (AST). Rare: Hepatic function abnormal.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Very rare: Hepatocellular damage.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>S</u><u>kin and subcutaneous tissue disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Rash, pruritus, hyperhidrosis, rash erythematous, urticaria, alopecia. Rare: Dermatitis, purpura.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Very rare: Oedema and bullous reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Musculoskeletal and connective tissue disorders</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Arthralgia</p><p style="direction:ltr">Rare: Bone pain, muscle spasms, myalgia.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Renal and urinary disorders</u></p><p style="direction:ltr">Rare: Nocturia, micturition disorders, increase in blood urea nitrogen and creatinine levels.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>General disorders and administration site conditions</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Uncommon: Malaise, face oedema. Rare: Asthenia.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>C. Description of selected adverse events.</u> N/A</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>D. Pediatric population.</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Lornoxicam is not recommended for use in children and adolescents below age 18 due to a lack of data on safety and efficacy.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>E. Other special population</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Elderly</p><p style="direction:ltr">No special dosage modification is required for elderly patients above age 65 unless renal or hepatic function is impaired. Lornoxicam should be administered with precaution as gastrointestinal adverse effects are less well tolerated in this group (see section 4.4).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Renal impairment</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">For patients with mild to moderate renal impairment the maximum recommended daily dose is 12 mg divided in 2 or 3 doses (see section 4.4).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Hepatic impairment</p><p style="direction:ltr">For patients with moderate hepatic impairment the maximum recommended daily dose is</p><p style="direction:ltr">12 mg divided in 2 or 3 doses (see section 4.4).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4.).</p><p style="direction:ltr"><img src="data:image/png;base64,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" alt="" width="505" height="209" vspace="0" hspace="0" border="0" style="width:505px;height:209px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">At this time, there is no experience of overdose to permit definition of the consequence of an overdose, or to suggest specific managements. However, it can be expected that after an overdose with lornoxicam, the following symptoms can be seen: Nausea, vomiting, cerebral symptoms (dizziness, disturbances in vision). Severe symptoms are ataxia ascending to coma and cramps, liver and kidney damages and maybe coagulation disorders.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">In the case of a real or suspected overdose, the medicinal product should be withdrawn. Due to its short half-life, lornoxicam is rapidly excreted. Lornoxicam is not dialysable. No specific antidote is known to date. The usual emergency measures including gastric lavage should be considered. Based on principles, only administering activated charcoal immediately after the intake of lornoxicam can lead to diminished absorption of the preparation. Gastrointestinal disorders can for example be treated with a prostaglandin analogue or ranitidine.</p><p style="direction:ltr">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">Pharmacotherapeutic group: antiinflammatory and antirheumatic products, non-steroids, oxicams ATC code: M01 AC05</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Lornoxicam is a non steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. Lornoxicams mode of action is mainly related to the inhibition of the prostaglandin synthesis (inhibition of the cyclooxygenase enzyme) leading to desensitisation of peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception which seems to be independent of anti- inflammatory effects has also been suggested.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Lornoxicam has no effect on vital signs (e.g. body temperature, respiratory rate, heart rate, blood pressure, ECG, spirometry).</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">The analgesic properties of lornoxicam have been demonstrated successfully in several clinical trials during development of the drug.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Due to a local gastrointestinal irritation and a systemic ulcerogenic effect related to the inhibition of prostaglandin (PG)-synthesis, gastrointestinal sequela are common undisirable effects after treatment with lornoxicam as seen with other NSAIDs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr"><u>Absorption</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Lornoxicam is absorbed rapidly and almost completely from the gastrointestinal tract. Maximum plasma concentrations are achieved after approximately 1-2 hours. The absolute bioavailability of lornoxicam is 90-100 %. No first-pass effect has been observed. The mean elimination half-life is 3-4 hours.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Simultaneous intake of lornoxicam with meals reduces Cmax by approximately 30 % and Tmax increases from 1.5 to 2.3 hours. The absorption of lornoxicam (calculated on AUC) can be reduced up to 20 %.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Distribution</u></p><p style="direction:ltr">Lornoxicam is found in the plasma in unchanged form and as its hydroxylated metabolite. The plasma protein binding of lornoxicam is 99 % and not concentration dependent.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>B</u><u>iotransformation</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Lornoxicam is extensively metabolised in the liver, primarily to the inactive 5&ndash; hydroxylornoxicam by hydroxylation. CYP2C9 is involved in this biotransformation of lornoxicam. Due to genetic polymorphism, slow and extensive metabolisers exist for this enzyme which could result in markedly increased plasma levels of lornoxicam in slow metabolisers. The hydroxylated metabolite exhibits no pharmacological activity. Lornoxicam is metabolised completely, and approximately 2/3 is eliminated via the liver and 1/3 via the kidneys as inactive substance.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">When tested in animal models, lornoxicam did not induce liver enzymes. From clinical trial data there is no evidence of accumulation of lornoxicam after repeated administrations, when given according to recommended dosage. This finding was supported by drug monitoring data from one year studies.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr"><u>Elimination</u></p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">The mean elimination half-life of the parent compound is 3 to 4 hours. After oral administration about 50% is excreted in the faeces and 42% through the kidneys, mainly as 5-hydroxylornoxicam. The elimination half-life of 5-hydroxylornoxicam is about 9 hours after a parenteral single or twice daily dose.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">In elderly patients above age 65, the clearance is reduced with 30-40%. Apart from reduced clearance, there is no significant change in the kinetic profile of lornoxicam in elderly patients.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">There is no significant change in the kinetic profile of lornoxicam in patients with renal or hepatic failure, except for accumulation in patients with chronic liver disease after 7 days of treatment with daily doses of 12 and 16 mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Lornoxicam caused renal toxicity and gastrointestinal ulceration single- and repeat-dose toxicity studies in several species.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">In animals, administration of prostaglandin synthesis inhibitor has been shown to result in increased pre- and post- implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">In rat, lornoxicam impaired fertility (effects on ovulation and implantation), and affected the pregnancy and delivery. In rabbit and rat, lornoxicam caused premature closure of the ductus arteriosus due to inhibition of cyclooxygenase.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">Core:</p><p style="direction:ltr">Lactose monohydrate, Microcrystalline cellulose, Povidone, Croscarmellose sodium</p><p style="direction:ltr">Magnesium stearate</p><p style="direction:ltr">&nbsp;</p><p style="direction:ltr">Film: Opadry White 03F28421</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">Xelorni is supplied as blisters (PVC /ALU blister). Packs of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="direction:ltr">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>